8-K - Theriva Biologics, Inc. (0000894158) (Filer)

424B5 - Theriva Biologics, Inc. (0000894158) (Filer)

EFFECT - Theriva Biologics, Inc. (0000894158) (Filer)

8-K - Theriva Biologics, Inc. (0000894158) (Filer)

8-K - Theriva Biologics, Inc. (0000894158) (Filer)

S-1/A - Theriva Biologics, Inc. (0000894158) (Filer)

10-K - Theriva Biologics, Inc. (0000894158) (Filer)

8-K - Theriva Biologics, Inc. (0000894158) (Filer)

S-1/A - Theriva Biologics, Inc. (0000894158) (Filer)

S-1 - Theriva Biologics, Inc. (0000894158) (Filer)

4 - Theriva Biologics, Inc. (0000894158) (Issuer)

4 - Theriva Biologics, Inc. (0000894158) (Issuer)

4 - Theriva Biologics, Inc. (0000894158) (Issuer)

4 - Theriva Biologics, Inc. (0000894158) (Issuer)

ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the closing of its previously announced "reasonable best efforts" public offering of 6,818,180 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 6,818,180 shares of common stock at a combined offering price of $1.10 per share and accompanying warrant (the "Offering"). The Company received aggregate gross proceeds of approximately $7.5 million, before deducting placement agent fees and oth

ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the pricing of its "reasonable best efforts" public offering for the purchase and sale of up to 6,818,180 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 6,818,180 shares of common stock at a combined offering price of $1.10 per share and accompanying warrant (the "Offering"). The Company expects to receive aggregate gross proceeds of approximately $7.5 million, before deducting placeme

- Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy had increased overall survival, progression free survival, and duration of response compared to patients treated with gemcitabine/nab-paclitaxel SoC - - VCN-01 was well-tolerated, with transient and reversible adverse events (AEs), meeting primary safety endpoint - - Greater differences between the treatment arms were observed in patients receiving 2 doses of VCN-01 - - Data to be reviewed during a Key Opinion Leader webinar Featuring Dr. Manuel Hidalgo Medina and Dr. Mike Pishvaian on Wednesday May 7th, 2025 at 0800 US EDT - ROCKVILLE, Md., May 07, 2025 (GLOBE

ROCKVILLE, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that a second Independent Data Monitoring Committee (IDMC) review of data from the VIRAGE Phase 2b clinical trial in newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) found that that VCN-01 was well tolerated in combination with standard-of-care chemotherapy (gemcitabine/nab-paclitaxel) and the adverse event (AE) profile was as expected for the patient population and the medications being studied. The IDMC, composed of key opinion leaders in

ROCKVILLE, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the Company's Management will be attending and presenting at the Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA. A company presentation will take place during the conference's Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference's Innovation track spotlights the most promising emerging biotech and healthcare companies advanc

– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 – – VCN-01 development bolstered by FDA award of Fast Track designation for the treatment of PDAC and Rare Pediatric Disease designation for retinoblastoma – – Received guidance from the FDA and EMA on Phase 3 pivotal trial design for VCN-01 in combination with standard-of-care chemotherapy for metastatic PDAC – –– As of December 31, 2024, Theriva Biologics reports $11.6 million in cash, which is expected to provide runway into Q3 2025 – ROCKVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), a diversified

ROCKVILLE, Md., March 05, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Steve Shallcross, Chief Executive Officer, and Manel Cascallo, PhD., General Director will present at the Q1 Investor Summit Virtual. Theriva's management team will participate in 1x1 meetings. Q1 Investor Summit VirtualFormat: PresentationPresenter: Steve Shallcross, CEO and Manel Cascallo, PhD., General DirectorPresentation Date and Time: Tuesday, March 11, 2025, 12:30 PM ETWebcast: Click Here About Theriva™ Biologics, Inc. Theriva™ Biologics (NYSE:

ROCKVILLE, Md., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the outcomes of a recent Type D meeting with the U.S. Food and Drug Administration (FDA) to obtain guidance on the design of a Phase 3 clinical study of lead clinical candidate VCN-01 in combination with standard-of-care chemotherapy for the treatment of metastatic pancreatic adenocarcinoma (PDAC). The Company recently announced the completion of target enrollment into the multinational VIRAGE Phase 2b clinical study evaluating intravenous VCN-01 in combinatio

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic pancreatic ductal adenocarcinoma Manufacturing funding awarded by the Spanish Government's National Knowledge Transfer Program Data and Safety Monitoring Committee Review of Phase 1b/2a SYN-004 in allogeneic hematopoietic cell transplant recipients recommends expansion to Cohort 3 Orphan Medicinal Product Designation granted by the European Commission to VCN-01 for the treatment of retinoblastoma Rare Pediatric Disease Designation granted by the FDA for the treatment of retinoblastoma Placed Second in International Competit

ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced selection as one of five finalists for Merck KGaA's EMEA Advance Biotech Grant. Finalists for the grant will present to a six-judge panel from Merck's Emerging Biotech group during BIO Europe 2024 in Stockholm, Sweden. Manel Cascalló, PhD., General Director - EU Subsidiary, Theriva Biologics, will present an overview of VCN-01, currently being studied in a Phase 2b clinical trial in first-line metastatic pancreatic cancer in combination with standard-of-care

– The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), with no safety concerns raised - - VIRAGE remains on track to complete enrollment in the first half of 2024- - As of December 31, 2023, Theriva Biologics reports $23.2 million in cash, which is expected to provide runway into the first quarter of 2025 - - Conference call and webcast to be held on Monday, March 25 at 8:30 a.m. ET - ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing ther

ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, March 25, 2024, at 8:30 a.m. ET to discuss its financial results for the full year ended December 31, 2023 and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) and using the conference ID: 13744453. Participants are asked to dial-in 15 minutes before the start of the call to register. Investors and th

- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024; multiple patients have received second doses of VCN-01, which continues to be well tolerated with a safety profile consistent with prior clinical trials - - Presented survival outcomes data from the Phase 1 investigator-sponsored study evaluating VCN-01 in combination with durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck at the European Society for Medical Oncology (ESMO) Congress 2023 - - Data from the Phase 1 investigator-sponsored stu

ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, November 13, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2023 and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) and using the conference ID: 13741546. Participants are asked to dial in 15 minutes before the start of the call to register. Investors and th

- Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma -Second doses of intravenous VCN-01 administered to patients in Spain and were well tolerated with a safety profile consistent with prior clinical trials - -VIRAGE remains on track to complete enrollment in the first quarter of 2024- - VCN-01 granted Orphan Drug Designation by the U.S. FDA for the treatment of pancreatic cancer – - Ramon Alemany, Ph.D., appointed as Senior Vice President of Discovery, strengthening the collaboration with the Institut Catala d'Oncologia (ICO) and the Biomedical Research Institute of Bellvitge (IDIBELL)-

ROCKVILLE, Md., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Tuesday, August 8, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2023 and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) and using the conference ID: 13739888. Participants are asked to dial in 15 minutes before the start of the call to register. Investors and the pub

– Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Presented data from the ongoing Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients at the 33rd European Congress of Clinical Microbiology & Infectious Disease; Cohort 2 continues to enroll patients – – As of March 31, 2023, Theriva Biologics reports $36.1 million in cash, which is expected to provide runway into the third quarter of 2024 – – Conference call and webcast to be held on Thursday, May 11th at 8:30 a.m. ET – ROCKVILLE, Md., May 11, 2023

ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, May 11, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2023 and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) and using the conference ID: 13738367. Participants are asked to dial in 15 minutes before the start of the call to register. Investors and the public

– Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Dosed the first patient in the investigator sponsored Phase 1 clinical trial of VCN-01 for patients with brain tumors – – Presented positive safety and pharmacokinetic data from the ongoing Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients at 2023 Tandem Meetings Transplantation & Cellular Therapy Meetings; Dosed the first patient in Cohort 2 – – As of December 31, 2022, Theriva Biologics reports $41.8 million in cash, which is expected to provide runway into the

ROCKVILLE, Md., March 24, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, March 30, 2023, at 8:30 a.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2022 and provide a corporate update. The call was originally scheduled for Monday, March 27, 2023, at 8:30 a.m. ET. Individuals may participate in the live call via telephone by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) and using the conference ID: 13736047. Part